News & Updates

Show Multimedia Only

Rescue combo therapy outshines albuterol alone for mild asthma

12 Nov 2025 by

As-needed treatment with the combination of albuterol plus budesonide works better than albuterol alone for preventing severe exacerbations in patients with uncontrolled mild asthma, according to the phase IIIb BATURA trial.

Rescue combo therapy outshines albuterol alone for mild asthma

12 Nov 2025

Rapid and reliable detection of SARS-CoV-2 and influenza in real-world settings

12 Nov 2025

As seasonal influenza returns amid ongoing SARS-CoV-2 circulation, rapid differentiation between these infections has become crucial for enabling early and effective patient care. Researchers conducted the largest prospective, multicentre evaluation to date of the Panbio COVID-19/Flu A&B Panel (Abbott)—a single-strip antigen test designed to detect SARS-CoV-2, influenza A, and influenza B from mid-turbinate nasal swabs (NMT) in symptomatic individuals. [J Clin Microbiol 2024;62:e0020724]

Rapid and reliable detection of SARS-CoV-2 and influenza in real-world settings

12 Nov 2025

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

11 Nov 2025 by

A 3-day course of oral nafithromycin is equally efficacious as the 7-day course of oral moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP) in adults, as shown in a phase III study.

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

11 Nov 2025

Chemo-free treatment combination prolongs survival in previously treated mCRC

10 Nov 2025 by

Treatment with the multitargeted tyrosine-kinase inhibitor zanzalintinib, when combined with atezolizumab, confers an overall survival benefit in previously treated metastatic colorectal cancer (mCRC), according to the phase III STELLAR-303 trial.

Chemo-free treatment combination prolongs survival in previously treated mCRC

10 Nov 2025

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

10 Nov 2025

In patients with chronic ischaemic heart disease (IHD), the use of oral nitrates helps lower the risk of open-angle glaucoma (OAG) and primary open-angle glaucoma (POAG), according to a retrospective study.

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

10 Nov 2025

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

09 Nov 2025 by

In the frontline treatment of patients with HER2-expressing locally advanced or metastatic urothelial cancer, the combination of disitamab vedotin plus toripalimab yields a clinically meaningful and significant increase in survival compared with chemotherapy, as shown in the phase III RC48-C016 trial.

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

09 Nov 2025

Bexicaserin shows promise in developmental and epileptic encephalopathies

08 Nov 2025

In the treatment of patients with developmental and epileptic encephalopathies (DEEs), the selective serotonin 5-HT2C receptor agonist bexicaserin is well tolerated and appears to reduce the frequency of countable motor seizures, according to a phase Ib/IIa study.

Bexicaserin shows promise in developmental and epileptic encephalopathies

08 Nov 2025

Managing obesity-related cardiovascular risk in primary care

08 Nov 2025

Obesity and overweight are now among the most pervasive health challenges worldwide, contributing substantially to the burden of cardiovascular disease (CVD). In Singapore, the 2022 National Population Health Survey reported that one in nine adults is obese, while nearly a third are overweight—a trend that continues to climb. [https://isomer-user-content.by.gov.sg/3/28c3b8f9-9216-46be-8fc9-b614098666a9/nphs-2022-survey-report_final.pdf]

Managing obesity-related cardiovascular risk in primary care

08 Nov 2025

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

07 Nov 2025 by

For patients who are struggling to lose weight after metabolic bariatric surgery, treatment with liraglutide boosts weight-loss outcomes and helps avoid conversion surgery, as shown in a randomized clinical trial.

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

07 Nov 2025

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

07 Nov 2025 by

The use of bemarituzumab in combination with chemotherapy provides statistically significant survival benefits among patients with advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC) in the primary analysis of the phase III FORTITUDE-101 trial.

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

07 Nov 2025

News & Updates

Filter by Specialty:

Specialty:

Rescue combo therapy outshines albuterol alone for mild asthma

Rescue combo therapy outshines albuterol alone for mild asthma

Rapid and reliable detection of SARS-CoV-2 and influenza in real-world settings

Rapid and reliable detection of SARS-CoV-2 and influenza in real-world settings

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

Chemo-free treatment combination prolongs survival in previously treated mCRC

Chemo-free treatment combination prolongs survival in previously treated mCRC

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

Bexicaserin shows promise in developmental and epileptic encephalopathies

Bexicaserin shows promise in developmental and epileptic encephalopathies

Managing obesity-related cardiovascular risk in primary care

Managing obesity-related cardiovascular risk in primary care

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer